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Accurate interpretation of genetic 
variants in sudden unexpected 
death in infancy by trio‑targeted 
gene‑sequencing panel analysis
Keita Shingu1,2, Takehiko Murase1, Takuma Yamamoto1,4*, Yuki Abe1, Yoriko Shinba1, 
Masahide Mitsuma1,2, Takahiro Umehara1, Hiromi Yamashita3 & Kazuya Ikematsu1
In sudden unexpected death in infancy cases, postmortem genetic analysis with next‑generation 
sequencing potentially can extract candidate genes associated with sudden death. However, it 
is difficult to accurately interpret the clinically significant genetic variants. The study aim was to 
conduct trio analysis of cases of sudden unexpected death in infancy and their parents to more 
accurately interpret the clinically significant disease‑associated gene variants associated with 
cause of death. From the TruSight One panel targeting 4813 genes we extracted candidate genetic 
variants of 66 arrhythmia‑, 63 inherited metabolic disease‑, 81 mitochondrial disease‑, and 6 salt‑
losing tubulopathy‑related genes in 7 cases and determined if they were de novo or parental‑derived 
variants. Thirty‑four parental‑derived variants and no de novo variants were found, but none appeared 
to be related to the cause of death. Using trio analysis and an in silico algorithm to analyze all 4813 
genes, we identified OBSCN of compound heterozygous and HCCS of hemizygous variants as new 
candidate genetic variants related to cause of death. Genetic analysis of these deceased infants 
and their living parents can provide more accurate interpretation of the clinically significant genetic 
variants than previously possible and help confirm the cause of death.
Sudden unexpected death in infancy (SUDI) is a term that has been variably used to refer to all cases of sudden 
and unexpected deaths in infancy, including sudden infant death syndrome (SIDS)1. In 2015, SIDS was the third 
leading cause of death at age 0 in Japan, with a mortality rate of 9.5 per 100,000  population2. However, SUDI 
is thought to be more common because of the difficult distinction between SIDS and accidental asphyxia or 
natural diseases, such as arrhythmias and inherited metabolic  disease2. Arrhythmia, inherited metabolic disease, 
mitochondrial disease, and salt-losing tubulopathy are linked to sudden unexpected death (SUD)3–13. Thus, 
SUDI is considered to be the severest form of various related diseases. The standard methods of determining 
the cause of death in SUDI cases include conventional autopsy (macroscopic autopsy and detailed microscopic 
 examination14), toxicology, biochemical tests, and recently, metabolic  autopsy15. However, in most SUDI cases, 
these methods do not reveal the exact cause of death, hence the urgent need to develop novel diagnostic methods.
Recently, some studies have shown that genetic analysis using next-generation sequencing (NGS) of SUDI 
cases was effective in diagnosing arrhythmias and inherited metabolic disease 9,10. On the other hand, it has been 
reported that some of the variants in arrhythmia-related genes found in SUD cases were not associated with cause 
of  death16,17. In other words, an accurate interpretation of the association between variants in disease-related 
genes found in SUD cases and sudden death is important in determining cause of death. However, even if vari-
ants in arrhythmia-related genes are found, it is difficult to obtain findings that can be judged as arrhythmia 
from macroscopic, pathological, and biochemical examinations. Most conventional NGS studies were limited 
to genetic analysis of sudden death cases only. Recently, familial gene analysis of cardiac sudden death cases 
and their parents was shown to be effective for diagnosis of cause of  death18–25. However, most family analy-
ses have targeted genes for arrhythmia, so it would be useful to target not only those genes but also any other 
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disease-related genes. Furthermore, few studies have reported family genetic analyses with NGS that focused 
on SUDI. Since SUDI is considered to be the severest form of various diseases, it would be useful to analyze the 
genes associated not only with arrhythmia but also with other diseases that can cause sudden death. Therefore, 
we thought that genetic analysis of SUDI cases and their parents would lead to a more accurate interpretation 
of the clinically significant genetic variants associated with cause of death.
The study aim was to perform trio analysis of SUD infants and their parents to interpret the clinically sig-
nificant disease-associated gene variants associated with the cause of death more accurately. In addition, we 
used trio analysis to extract novel candidate gene variants and examined whether these extracted variants were 
associated with cause of death.
Results
Case collection. Among the 24 autopsied cases, 17 could not be diagnosed using conventional methods. 
From the 17 undiagnosed cases, 9 patients’ parents gave consent for whole-genome sequencing. One of the nine 
cases was diagnosed with carnitine palmitoyltransferase II deficiency by metabolic  autopsy26. In another case, 
we could not extract a sufficient amount of DNA for targeted gene-sequencing panel analysis. A total of seven 
SUDI cases (two males, five females; age range: 3 months–2 years) were selected (Fig. 1). The case 2 parents had 
a consanguineous marriage (Table 1).
Target sequence of sudden death cases. On average, ~ 17.5 million total reads were produced and ~ 11.9 
million reads mapped to the targeted region in each sample. The mean coverage of the coding sequence was 
101.5 ± 33.7 reads, with an overall average gene level coverage ≥ 20 reads of 93.0% ± 10.7%. After the filtering 
steps, 1897 variants in the 4813 target genes were identified, which corresponded to an average of 271 variants 
per case.
Detected variants aligned to the 216 target genes. Thirty-four (18 non-synonymous and 16 syn-
onymous) detected variants were aligned with the 216 target genes. Eleven arrhythmia-, two cardiomyopathy-, 
three metabolic disease-, fifteen mitochondrial disease-, and three salt-losing tubulopathy-related genes were 
Autopsy under 2 years old
n = 24
・Pneumonia  n = 1
・Bronchitis  n = 1
・Sepsis  n = 2
・Drowning  n = 2
・Traumatic brain damage  n = 1Autopsy negative sudden unexpected death 
n = 17
Whole genome trio sequencing were allowed
n = 9
Whole genome trio sequencing was not allowed
n = 8
Diagnosed by conventional method
n = 7
Next generation sequencing was performed
n = 7
Sufficient DNA for exome sequencing was not isolated  
n = 1
Diagnosed CPT II deficiency in the previous metabolic autopsy 
n = 1
Figure 1.  Flowchart of the selection process showing the number of participants in this study. Autopsy negative 
means that the case was not diagnosed even after macroscopic and microscopic examinations and a toxicology 
examination. Abbreviation: CPT II: carnitine palmitoyltransferase II.
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included. All of these genetic variants were heterozygous and did not contain any de novo gene variants (Tables 2 
and 3, Supplementary Table 1, and Fig. 2).
Arrhythmia‑ and cardiomyopathy‑related gene variants. Most cases of genetic arrhythmia have 
autosomal dominant (AD) inheritance, and a familial history is not always present. Sporadic cases are mostly 
caused by de novo  variant9. Case 1 had Asp85Asn-KCNE1, AD inheritance of a long QT syndrome (LQTS)-
related gene variant. This variant was reported to be associated with LQTS and suggested as a possible cause 
of death in  SUDI9,27. The same variant was found in the female infant’s healthy living mother. Case 4 had 
Arg160Trp-MYBPC3, AD inheritance of a cardiomyopathy-related gene variant suspected to be harmful by in 
silico analysis. This variant reportedly could not be ruled out as a pathogenic  variant28. The female infant’s father 
had the same variant but did not develop cardiomyopathy. Case 5 had Gln2730Arg-AKAP9, AD inheritance of 
an LQTS-related gene variant. AKAP9 variants have been reported to be associated with LQTS type  1129, but 
Gln2730Arg-AKAP9 has not previously been reported to be associated with LQTS type 11. The female infant’s 
living father had the same variant. Five of seven cases had synonymous variants that were inherited from either 
of the parents. In silico analysis showed that all of them were benign.
Metabolic disease‑, mitochondrial disease‑, and salt‑losing tubulopathy‑related gene vari‑
ants. Most inherited metabolic disease, mitochondrial disease, and salt-losing tubulopathy have autosomal 
recessive (AR) or X-chromosomal recessive inheritance. Homozygous amino acid changes or at least two het-
erozygous amino acid changes are necessary to cause these  diseases9,30–33.
Case 1 had Leu21 = -SDHAF2, AD inheritance of a paraganglioma-related gene variant. TraP Score of 
Leu21 = -SDHAF2 was 0.089, which meant that the variant was benign. In addition, her mother had the same 
variant. The diseases associated with the other 20 gene variants are all forms of AR inheritance. Since the variants 
in the cases were all heterozygous, these diseases were unlikely to have developed and led to death.
Detected de novo, homozygous, compound heterozygous, and hemizygous variants aligned 
with all 4813 genes in TruSight One. A total of 12 de novo variants in 10 genes, 4 homozygous vari-
ants in 4 genes, compound heterozygous variants in 4 genes, and 4 hemizygous variants in 4 genes were found 
in < 0.1% of the Japanese population. All de novo variants were heterozygous (Table 4, Supplementary Table 2). 
As of August 2021, a search conducted on PubMed using these 20 gene names and the terms “sudden,” “infant,” 
and “death” as keywords returned no papers related to SUDI (Fig. 2).
Table 1.  Summary of SUDI cases and their parents and results of sequencing analysis. Trio 2 parents had a 
consanguineous marriage.












Case 3 M Female 12,491,263 1,494,300,281 10,542,312 85 82
Father – – 21,352,420 3,069,189,175 14,139,830 124.2 96.9
Mother – – 15,157,248 2,148,307,197 10,561,623 91.9 94.1
2
Case 1Y8M Female 14,318,515 1,727,573,727 10,812,331 86.6 88.4
Father – – 18,296,664 2,543,663,623 12,035,904 101.2 96.4
Mother – – 20,837,322 2,915,885,754 13,477,515 113.9 95.5
3
Case 3 M Female 14,482,070 2,037,650,595 9,811,216 84.8 93.8
Father – – 17,437,111 2,451,099,641 11,825,077 101.7 95.6
Mother – – 17,211,772 2,432,468,086 11,476,012 99.2 95.1
4
Case 3 M Female 20,731,617 2,981,575,844 14,700,318 129.4 97
Father – – 17,000,730 2,364,257,419 12,397,912 106.9 95.7
Mother – – 14,574,427 2,070,845,131 10,579,807 92.6 94.7
5
Case 4 M Female 16,762,916 2,344,786,584 10,088,104 85.6 95.3
Father – – 17,644,526 2,424,775,119 11,695,666 100.4 92.1
Mother – – 22,127,138 2,971,368,392 15,889,907 134.2 95.4
6
Case 2Y Male 16,932,684 2,353,138,678 10,368,292 87.6 95.8
Father – – 15,497,810 2,083,213,340 10,775,295 92.5 79.7
Mother – – 23,474,057 3,265,426,029 16,050,903 136.9 96.8
7
Case 6 M Male 18,961,926 2,635,964,881 11,983,786 100.7 96.2
Father – – 19,247,261 2,676,991,782 12,048,382 101.9 95.5
Mother – – 14,468,867 2,009,952,449 8,700,560 75.2 80.2
4
Vol:.(1234567890)
Scientific Reports |        (2021) 11:21532  | https://doi.org/10.1038/s41598-021-00962-8
www.nature.com/scientificreports/
Discussion
First, we examined the significance of variants in disease-associated genes that could cause sudden death by 
performing trio analysis of SUDI cases and the parents. Arrhythmias, inherited metabolic disease, mitochondrial 
disease, and salt-losing tubulopathy were considered as candidate diseases that could cause SUDI since these 
diseases were difficult to diagnose because there are few specific findings at autopsy.
Arrhythmias and inherited metabolic disease have been reported to be associated with  SUDI3–10. In this 
study, we adopted genes related to arrhythmia and inherited metabolic disease that we used in a previous study 
as candidate  genes9. In particular, D85N_KCNE1 has been previously reported as a genetic variant associated 
with LQTS. In the present study, the same variant was also found in the infant’s mother, which could suggest 
that this variant alone was not sufficient to cause LQTS.
Mitochondrial disease is a type of inherited metabolic disease that occurs in about 1 in 5000  births34. There 
have been reports of postmortem diagnosis of mitochondrial  disease11. Ohtake et al. reported that about 9% of 
those diagnosed with mitochondrial disease were cases of  SUDI12. In addition, we adopted this gene as a candi-
date because most mitochondrial diseases are caused by variants in human nuclear  DNA35.
Salt-losing tubulopathy is a group of diseases, including Bartter syndrome and Gitelman syndrome, character-
ized by hypokalemic metabolic alkalosis as a common  feature36. Electrolyte abnormalities cannot be established 
at general autopsy. In one case, Bartter syndrome was diagnosed by postmortem genetic  testing13, and salt-losing 
tubulopathy-related genes were used as candidate genes.
After the filtering step, 34 variants were found aligned with the 31 target genes. All of these variants were 
heterozygous. Software Implemented Fault Tolerance (SIFT), PolyPhen2, and TraP Score revealed a total of nine 
harmful missense variants. Genetic analysis of this case alone would have determined that these variants were 
likely to cause abnormal protein function and were associated with cause of death. In particular, the KCNE1, 
MYBPC3, and AKAP9 genes that were associated with LQTS or cardiomyopathy would have been suspicious 
as genes associated with cause of death because of an AD mode of  inheritance27,37,38. These were sporadic cases 
without any family history of sudden death, and none of the AD-inherited arrhythmia-related gene variants in 
these cases were de novo. In general, if the proband had an AD genetic disease, at least some of the relatives would 
have the same symptoms. Therefore, these disease-associated genetic variants alone would not have caused the 
SUDI, as the relatives, including the parents, had not experienced SUD, obviously. These family histories and 
trio analysis results suggest that some of the variants in SUDI cases could not be involved in the development 
of the disease, although the same variants were categorized as pathological by in silico analysis or by the results 
of experimentation.
Table 2.  Arrhythmia-, inherited metabolic disease-, mitochondrial disease-, and salt-losing tubulopathy-
related genes investigated in this study. PCCD: progressive cardiac conduction disturbance, CPVT: 
catecholaminergic polymorphic ventricular tachycardia, ARVC: arrhythmogenic right ventricular 
cardiomyopathy, OXPHOS: oxidative phosphorylation.
Arrhythmia
Brugada syndrome SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B, KCNE3, SCN3B, KCNH2, KCNJ8, CACN2D1, RANGRF, KCNE5, KCND3, HCN4, SLMAP, TRPM4, SCN2B, FGF12, SCN10A
Long QT syndrome KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP9, SNTA1, KCNJ5, CALM1, CALM2
Short QT syndrome KCNH2, KCNQ1, KCNJ2, CACNA1C, CACNB2, CACN2D1
PCCD SCN5A, LMNA, EMD, SCN1B, TRPM4, GJA5
CPVT RYR2, CASQ2, TRDN, CALM1, CALM2
ARVC PKP2, DSC2, DSG2, JUP, DSP
Others CAMK2D, CALM3, DES, DPP6, GJA1, GJC1, KCNA5, KCNE4, KCNIP2, KCNJ3, KCNK17, KCNN2, MYBPC3, MYH6, MYH7, NCS1, NKX2-5, NPPA, PLN, SLC8A1, TAZ, TBX3TBX5, TCAP
Inherited metabolic disease
Organic acid ACAT1, AUH, ETFA, ETFB, ETFDH, GCDH, HLCS, HMGCL, HMGCS2, IVD, LMBRD1, MCCC1, MCCC2, MMAA, MMAB, MMACHC, MMADHC, MUT, OPA3, PCCA, PCCB
Amino acid ASL, ASS1, BCKDHA, BCKDHB, BCKDK, CBS, CPS1, DLD, DBT, MAT1A, NAGS, OTC, PAH, PCBD1, PTS, QDPR, SLC25A13
Fatty acid oxidation ACADM, ACADVL, CPT1A, CPT2, HADHA, HADHB, SLC22A5, SLC25A20
Carbohydrate GALE, GALK1, GALT
Others ABCD4, BTD, DNAJC19, GCH1, HCFC1, HSD17B10, MTHFR, MTR, MTRR, SLC52A1, SLC52A2, SLC52A3, SLC5A6, SPR
Mitochondrial disease
OXPHOS system
NDUFA2, NDUFA9, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFB3, NDUFB9, NDUFS1, NDUFS2, NDUFS3, 
NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFA1, ACAD9, NDUFAF1, NDUFAF2, NDUFAF4, NDUFAF5, NDUFAF6, 
FOXRED1, SDHA-D, SDHAF1, SDHAF2, UQCRB, UQCRQ, BCS1L, TTC19, COX6B1, NDUFA4, COX4I2, SURF1, 
SCO1, SCO2, COX10, COX15, LRPPRC, COA5, ATP5E, ATPAF2, TMEM70, COQ2, COQ4, COQ6, PDSS2, ETFDH, 
ADCK3
Mitochondrial translation MRPS16, MRPS22, GFM1, TUFM, TSFM, PUS1, MTFMT, AARS2, DARS2, EARS2, GARS, MARS2, RARS2, SARS2, YARS2
Nucleotide maintenance TYMP, RRM2B, SLC25A4, TK2, MPV17, DGUOK, SUCLA2, SUCLG1, DNA2, SLC25A3, GFER
Others POLG, c10orf2, POLG2, OPA1, PINK1, DNM1L
Salt losing tubulopathy BSND, CLCNKA, CLCNKB, KCNJ1, SLC12A1, SLC12A3
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Second, candidate variants causing sudden infant death were extracted for all 4813 genes in the TruSight One 
panel. The incidence of SIDS in families is extremely low, and most cases are  sporadic39. It is generally believed 
that rare variants are associated with rare  diseases40, and diseases that can cause SUDI are considered to be one 
of the most severe of rare diseases. If SUDI cases with no family history of SUD manifested genetic variants that 
caused the sudden death, the variants were considered to be de novo. In addition, the variants of homozygotes 
or compound heterozygotes in SUDI cases and heterozygotes in their parents were extracted. Similarly, the vari-
ants of X-chromosome hemizygotes in SUD in male infancy and heterozygotes in their mothers were extracted.
We found eight de novo heterozygous missense variants in seven genes, three homozygous missense vari-
ants in three genes, eleven compound heterozygous missense variants in three genes, and two X-chromosome 
hemizygous missense variants in two genes (Table 4). These gene names and “sudden,” “death,” and “infant” were 
entered into PubMed as search terms. No papers described the association between these genes and SUDI. There-
fore, some of these variants might be novel variants associated with cause of SUDI. Of these genes, we focused 
on two as biologically plausible candidate genes potentially associated with cause of death, OBSCN and HCCS.
Obscurin, which is encoded by the OBSCN gene, has an important role in the organization of sarcomeres 
during myofibril formation and the regular alignment of sarcoplasmic  reticulum41. OBSCN variants may be 
monogenic causes of cardiomyopathy or contribute to the disease phenotype in concert with other  variants42. In 
addition, inhibition of sarcomeric activity may cause arrhythmogenesis. It has also been reported that variants in 
Table 3.  Results of known arrhythmia-, inherited metabolic disease-, mitochondrial disease-, and salt-
losing tubulopathy-related variants. MTHFR: methylenetetrahydrofolate reductase, CPT: carnitine 
palmitoyltransferase, AD: autosomal dominant, AR: autosomal recessive.
Case Gene Variant Coordinate Amino Acids Zygosity Heredity
Genetic 
phenotype Inheritance SIFT PolyPhen-2 dbSNP ID
1
KCNE1 C > C/T 35,821,680 Asp85Asn Heterozygote Mother Long QT syndrome AD
Deleterious 
(0.03) Benign (0.441) rs1805128
CLCNKB T > T/C 16,373,054 Ile85Thr Heterozygote Father Bartter syn-drome type 3 AR Deleterious (0) Benign (0.097) rs202202425




AR Deleterious (0) Probably dam-aging (1) rs200758718










AR tolerated (0.31) Benign (0.122) –









MYBPC3 G > G/A 47,371,592 Arg160Trp Heterozygote Father Cardiomyo-pathy AD Deleterious (0)
Probably dam-
aging (0.998) rs193068692














CPT1A A > A/C 68,529,142 Leu630Arg Heterozygote Mother CPT deficiency type IA AR
Tolerated 
(0.35) Benign (0.024) –
5
AKAP9 A > A/G 91,712,512 Gln2730Arg Heterozygote Father Long QT syndrome AD –
Possibly dam-
aging (0.474) rs80191629
CACNA1C G > G/A 2,795,380 Arg1993Gln Heterozygote Mother Long QT/Short QT syndrome AD – – rs190288386









AR tolerated (0.5) Benign (0.002) –
7
CACNA1C G > G/A 2,795,380 Arg1993Gln Heterozygote Mother Long QT/Short QT syndrome AD – – rs190288386




AR Tolerated (1) Benign (0) –
PUS1 TG > TG/T 132,414,323 Gly20Aspf-sTer115 Heterozygote Mother
Myopathy, Lac-
tic acidosis AR – – –
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the sarcomeric gene may have caused sudden cardiac death in a case of infant death without a cardiomyopathy 
 phenotype43. In addition, the association of the OBSCN variant with a case of sudden cardiac death in an 8-year-
old girl has also been  reported44. Case 4 had maternal Arg1060Gln-OBSCN and paternal Ser5880Asn-OBSCN 
by compound heterozygotes. We speculated that these two heterozygous variants could be involved in sudden 
death by compound heterozygotes.
Holocytochrome c-type synthase, encoded by HCCS on the X chromosome, is located on the outer surface 
of the inner mitochondrial membrane and catalyzes covalent attachment of heme to both Cytc and  Cytc145. 
Cytc transfers electrons from electron-transfer complex III to complex IV in the mitochondria to promote ATP 
production. The HCCS variant at domain IV reduced expression of HCCS and also impaired release of  Cytc46. 
These suggest that HCCS plays an important role in mitochondrial function. Mitochondrial dysfunction can 
lead to arrhythmia and sudden  death47. In addition, it has been found that HCCS also has an important role 
in apoptosis and that the HCCS variant is associated with microphthalmia with linear skin defects syndrome, 
which is an X-linked male-lethal  disorder45,48. These results suggest that HCCS is an essential protein for vital 
function. Case 7, a 6-month-old boy, had hemizygous Ala248Ser-HCCS in domain IV. The in silico algorithms 
predicted that it was deleterious and probably damaging, so we speculated that this variant was associated with 
(2)  Extracted novel candidate gene variants of the cause of 





・1% < (ExAC: East Asian frequency)
Raw VCF file from SUD in infancy and living their parents (data for 21 people from 7 families)
Extracted variants to be analyzed
No variants reported about an association
between these genes and sudden infant death
1897 variants found in seven cases
Trio analysis and frequency in Japan less than 0.1%
・Twelve de novo heterozygous variants in ten genes
・Four homozygous variants in four genes
・Fourteen compound heterozygous variants in four genes
・Four hemizygous variants in four genes on X-chromosome
(1)  Detected variants aligned to the target 216 genes
SUD analysis only
Thirty-four heterozygous variants 7 cases 
(Table 3, Supplementary Table 1)
Nine harmful variants by in silico analysis
Three variants related autosomal dominant inheritance of
cardiomyopathy- or LQTS- related genes
No variants in 216 candidate genes of cause of death 
Trio analysis
Thirty-four all heterozygous variants inherited from each parents
SUD analysis only
OBSCN and HCCS focused on as biologically plausible 
novel candidate gene variants of cause of death
Figure 2.  Flowchart of the selection process showing candidate genes for cause of death in this study. The 
frequency of variants in Japanese people was based on ToMMo and HGVD data. (a) The target 216 genes 
are listed in Table 2. (b) All genes included in the TruSight One panel are shown in Supplementary Text 1. 
Abbreviations: SUD: sudden unexpected death.
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Table 4.  Results of de novo, homozygous, compound heterozygous, and hemizygous variants. ADHD: 
attention-deficit hyperactivity disorder, HIV: human immunodeficiency virus, AD: autosomal dominant, AR: 
autosomal recessive, XLD: X-linked dominant, XLR: X-linked recessive, N.R.: not reported.























AD – Unknown (0) rs373653069 N.R N.R




(0) – N.R N.R
CD209 C > C/T 7,810,559 Arg198Gln Heterozy-gote De novo





(0.001) rs41374747 N.R N.R






(0.002) rs746523028 5/9544 2/2418

























(0.013) – N.R N.R
PRKDC G > G/A 48,771,471 Arg2095Cys Heterozy-gote De novo
Immuno-
deficiency AR – – rs8178147 N.R N.R
4




(0.037) rs766325064 5/9546 N.R








KIR2DL4 G > G/A 55,316,398 Arg76Lys Heterozy-gote Father – – – – – N.R N.R
KIR2DL4 C > C/A 55,317,489 Gln149Lys Heterozy-gote
Ambigu-
ous – – – – rs796139593 N.R N.R
KIR2DL4 A > A/G 55,317,490 Gln149Arg Heterozy-gote
Ambigu-
ous – – – – rs746343340 N.R N.R
KIR2DL4 G > G/A 55,317,528 Glu162Lys Heterozy-gote
Ambigu-
ous – – – – rs540514355 N.R N.R
KIR2DL4 A > A/G 55,317,529 Glu162Gly Heterozy-gote
Ambigu-
ous – – – – rs796093143 N.R N.R
KIR2DL4 T > T/C 55,317,541 Leu166Pro Heterozy-gote
Ambigu-
ous – – – – rs112694450 N.R N.R
KIR2DL4 A > A/G 55,317,564 Ile174Val Heterozy-gote
Ambigu-
ous – – – – rs200435373 N.R N.R
6




(0) – N.R N.R



























AD, AR Tolerated (1) Benign (0) – 2/9546 N.R



















(0.023) – N.R N.R
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the cause of death. However, there is no report about the clinical significance of Ala248Ser-HCCS, so a functional 
analysis study is needed.
Trio analysis was thought to be useful for both evaluation of disease-related gene variants that could cause 
sudden death and extraction of novel candidate genes for sudden death. Trio analysis revealed that some variants 
in existing candidate genes for cause of death might be insufficient to cause death because these variants were 
inherited from either of the parents. This means that the postmortem genetic analysis of only SUDI cases could 
have led to misdiagnosis and was considered insufficient to determine cause of death.
We extracted genes with de novo, homozygous, compound heterozygous, and hemizygous variants and 
reviewed previous reports that had reported an association between these genes and SUDI. There were no reports 
of associations between the genes found in this study and SUDI, which suggested that OBSCN and HCCS from 
these extracted genes are novel candidate genes associated with death caused by gene dysfunction or diseases 
related to genetic variants. In a large cohort study of whole-exome sequencing for SIDS, no variants were found 
to be significantly more prevalent in SIDS cases than in the general  population49. Therefore, it may be difficult 
to identify gene variants that are candidates for cause of death by statistical analysis alone even when compar-
ing with a large sample of unrelated healthy subjects. If a sudden death case has an ultra-rare variant, it could 
be possible to determine the variant with pathological significance by examining whether the parents also have 
the variant.
Trio-targeted gene-sequencing panel analysis has an advantage over conventional methods for determin-
ing the cause of death. Genetic analysis of not only SUD deceased infants but also living parents can be a more 
exact inquiry for cause of death by SUDI. An autopsy is an investigation of the cause of death that is performed 
directly from a corpse. However, a genetic analysis of the SUD infants and their parents can provide more 
accurate interpretation of genetic variants than previously possible and help confirm a diagnosis of the cause 
of death. Furthermore, trio analysis can be performed in daily medical practice. It is important that the family 
members of those who have died suddenly should undergo standardized testing, including genetic  analysis50–52. 
We were careful to obtain informed consent from the parents before trio analysis. Additionally, if a trio analysis 
reveals a hereditary disease, it is possible to refer the patient for genetic counseling. Asymptomatic siblings can 
be provided with important genetic information of the deceased, which may enable detection of diseases before 
they develop. Furthermore, diagnosed individuals can receive appropriate treatment. Trio analysis data may 
eventually be utilized for child death reviews.
There were several study limitations that should be considered. Targeted gene-sequencing panel analysis was 
performed using a panel of 4813 genes; thus, targeted gene-sequencing panel analysis of genes not included in this 
panel and of the whole-genome sequence was not performed. TruSight One is a 4813-gene-sequencing panel that 
covers a wide range of known disease-associated genes, so it is helpful in clinical  diagnosis53. However, we believe 
that whole-exome analysis and whole-genome analysis are necessary to search for unknown genetic diseases. 
Additionally, mitochondrial genome sequencing was not performed. In the 4813 genes analyzed in this study, 
only limited variants, such as synonymous, missense, insertions, and deletions, were examined, and copy number 
polymorphisms were not analyzed. In this study, we investigated the association between the cause of death in 
SUD cases and arrhythmia and cardiomyopathy-related gene variants extracted by trio analysis. However, since 
incomplete penetrance diseases were identified in which the parents were asymptomatic and the child had a 
severe  phenotype54, further genetic studies including not only the parents, but also other relatives, are necessary.
In this study, we showed that trio analysis enabled more accurate interpretation of the clinically significant 
gene variants in SUD infants, which could help prevent misdiagnosis and extract novel genetic variants associ-
ated with SUDI. Trio analysis is a novel method that can be useful for determining cause of death because it also 
analyzes genetic information from living parents or relatives as well as from deceased victims. In addition, trio 
analysis may enable investigations of the cause of death even in hospitals. Trio analysis can identify unknown 
genetic variants that may be related to cause of death and help prevent SUDI in the future.
Methods
Study design and participants. The SUD cases of infants autopsied at ≤ 2  years of age were selected 
between April 2013 and March 2017. Informed consent for whole-genome sequencing and trio analysis were 
obtained from parents. A comprehensive forensic investigation, including a thorough examination of the death 
scene, a review of the clinical history, and performance of an autopsy that included macroscopic and micro-
scopic examinations and a toxicology examination, were performed in all cases.
Extraction of genomic DNA and genetic analysis. As reported  previously9, genomic DNA of SUDI 
deceased infants and their living parents was isolated from blood leukocytes and buccal mucosa, respectively, by 
using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan) in accordance with the manufacturer’s standard 
methods. A TruSight One sequencing panel (Illumina, San Diego, CA, USA) targeting 4813 disease-associated 
genes was used, and the sequencing was performed on an Illumina MiSeq (Illumina) (Supplementary Text 1).
Filtering steps for extraction of variants. As reported  previously9, the sequencing reads were mapped 
to the hg19 human reference genome sequence by using Variant Studio (version 3.0) software (Illumina). The 
variants with a low Q30 score or a read depth of < 30 were excluded. Copy number variation was not analyzed 
in this study. To identify putatively pathogenic variants, those with allele frequencies < 1% in East Asian ethnic 
subgroups were retained and listed by using data from the dbSNP (http:// www. ncbi. nlm. nih. gov/ proje cts/ SNP), 
the 1000 Genomes Project (http:// www. 1000g enomes. org), the NHLBI Exome Sequencing Project (http:// evs. 
gs. washi ngton. edu/ EVS), the Exome Aggregation Consortium (http:// exac. broad insti tute. org). In silico algo-
rithms, SIFT (http:// sift. jcvi. org), PolyPhen-2 (http:// genet ics. bwh. harva rd. edu/ pph2), and TraP Score (http:// 
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trap- score. org/ index. jsp)55, were used to predict whether the detected variants would affect the function of each 
protein. For the synonymous variants, the pathogenicity of the variant was confirmed by ClinVar (https:// www. 
ncbi. nlm. nih. gov/ clinv ar/).
Detected variants aligned with the target 216 genes. As reported  previously9, from the TruSight 
One panel targeting 4813 genes, we extracted sequence information from the 216 genes for inherited arrhyth-
mia, cardiomyopathy, metabolic diseases, mitochondrial disease, and salt-losing tubulopathy: 19 Brugada Syn-
drome genes, 15 LQTS genes, 6 short QT syndrome genes, 6 progressive cardiac conduction disturbance genes, 
5 catecholaminergic polymorphic ventricular tachycardia genes, 5 arrhythmogenic right ventricular cardiomyo-
pathy genes, 24 other cardiac genes, 63 inherited metabolic disease genes (such as fatty acid oxidation, amino 
acid, and organic acid disorders), 81 mitochondrial disease  genes30, and 6 salt-losing tubulopathy genes (such 
as Bartter syndrome and Gitelman syndrome)31–33. The gene list and criteria of gene selection are provided in 
Table 2. Single-nucleotide variations causing synonymous substitutions, non-synonymous substitutions, non-
sense substitutions, and insertions/deletions occurring in the coding regions were retrieved.
Extraction of de novo, homozygous, compound heterozygous, hemizygous variants of 
SUDI. After filtering steps, to extract < 0.1% of Japanese allele variant frequencies, the data from the Genome 
Cohort Study of Tohoku Medical Megabank Organization (ToMMo) (http:// ijgvd. megab ank. tohoku. ac. jp) 
and the Human Genetic Variation Database (HGVD) in the Human Genetic Variation Browser (http:// www. 
genome. med. kyoto-u. ac. jp/ SnpDB/ index. html) were referred to. Trio analysis was a comparative examination 
of genetic variants in SUDI deceased infants and their living parents. De novo variants, found in the SUD infants 
but not in their parents, were extracted by trio analysis. In the SUDI cases, homozygous variants or compound 
heterozygous variants that were heterozygous in their parents were extracted. In addition, in boy cases, hemizy-
gous variants in X chromosome were extracted. Of these extracted variants, allele frequencies ≥ 0.1% in the 
Japanese subgroup in ToMMo and HGVD were excluded. Especially for the compound heterozygous variants, 
both allele frequencies of < 0.1% each were adopted. Sudden infant death candidate gene names and the terms 
“sudden,” “infant,” and “death” were combined and searched in PubMed.
Sanger sequencing. Sanger sequencing was performed to confirm the detected candidate variants (OBSCN 
and HCCS), as previously described. The polymerase chain reaction primers were designed by using Primer3 
version 0.4.0 (https:// bioin fo. ut. ee/ prime r3-0. 4.0). (Supplementary Table 3.)
Ethical approval. Written informed consent was obtained from the parents for the use of the samples in this 
study, which was approved by the ethics committees of the Nagasaki University Graduate School of Medicine 
(20170504-3, 20200801-2). This study was performed in accordance with the Declaration of Helsinki.
Data availability
The main data supporting the findings of this study are available within the article and its Supplementary Infor-
mation. Additional data are available from the corresponding author upon reasonable request.
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